atenolol has been researched along with Cardiac Arrest, Sudden in 17 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the actions of beta-blocker (atenolol) and ACE inhibitor (enalapril) for the secondary prevention of the main cardiac complications after acute myocardial infarction (AMI)." | 9.08 | Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. Beijing Collaborative Study Group. ( Fan, Z; Wu, N, 1997) |
| "The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study included 9193 patients 55 to 80 years of age with essential hypertension and ECG LV hypertrophy by gender-adjusted Cornell product (CP) (RaVL+SV(3) [+6 mm in women])." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Olsen, MH; Thygesen, K; Wachtell, K, 2007) |
| "To investigate the actions of beta-blocker (atenolol) and ACE inhibitor (enalapril) for the secondary prevention of the main cardiac complications after acute myocardial infarction (AMI)." | 5.08 | Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. Beijing Collaborative Study Group. ( Fan, Z; Wu, N, 1997) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
| "Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4." | 3.72 | [Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004) |
| "The patient had no further arrhythmias on quinidine for 6 years until he inexplicably discontinued his medication and died suddenly shortly thereafter." | 1.30 | Familial sudden cardiac death associated with a terminal QRS abnormality on surface 12-lead electrocardiogram in the index case. ( Feld, GK; Finneran, W; Garg, A, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (47.06) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reno, CM | 1 |
| Skinner, A | 1 |
| Bayles, J | 1 |
| Chen, YS | 1 |
| Daphna-Iken, D | 1 |
| Fisher, SJ | 1 |
| Abu-Zeitone, A | 1 |
| Peterson, DR | 1 |
| Polonsky, B | 1 |
| McNitt, S | 1 |
| Moss, AJ | 1 |
| Morin, DP | 1 |
| Oikarinen, L | 1 |
| Viitasalo, M | 1 |
| Toivonen, L | 1 |
| Nieminen, MS | 2 |
| Kjeldsen, SE | 2 |
| Dahlöf, B | 3 |
| John, M | 1 |
| Devereux, RB | 2 |
| Okin, PM | 2 |
| Aronow, WS | 1 |
| Lindholm, LH | 2 |
| Edelman, JM | 1 |
| Ibsen, H | 2 |
| Borch-Johnsen, K | 1 |
| Olsen, MH | 2 |
| Snapinn, S | 1 |
| Wachtell, K | 2 |
| Ong, HT | 1 |
| Chong, AY | 1 |
| Lip, GY | 1 |
| Kanopskiĭ, SG | 1 |
| Staritskiĭ, AG | 1 |
| Bozhko, AA | 1 |
| Thygesen, K | 1 |
| Adamson, PB | 1 |
| Huang, MH | 1 |
| Vanoli, E | 1 |
| Foreman, RD | 1 |
| Schwartz, PJ | 1 |
| Hull, SS | 1 |
| Raza, A | 1 |
| Killip, T | 1 |
| Goodman, S | 1 |
| Hill, C | 1 |
| Bata, I | 1 |
| Fung, A | 1 |
| Higginson, L | 1 |
| Lam, J | 1 |
| Massel, D | 1 |
| McCans, J | 1 |
| Nasmith, J | 1 |
| Stanton, E | 1 |
| Thompson, C | 1 |
| Warnica, W | 1 |
| Langer, A | 1 |
| Lurje, L | 1 |
| Wennerblom, B | 1 |
| Tygesen, H | 1 |
| Karlsson, T | 1 |
| Hjalmarson, A | 1 |
| Wu, N | 1 |
| Fan, Z | 1 |
| Garg, A | 1 |
| Finneran, W | 1 |
| Feld, GK | 1 |
| Koudstaal, PJ | 1 |
| Algra, A | 1 |
| Pop, GA | 1 |
| Kappelle, LJ | 1 |
| van Latum, JC | 1 |
| van Gijn, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Prolonged Paced QRS Duration as a Marker of Sudden Cardiac Death in Subjects With Implantable Cardioverter-defibrillators[NCT01948206] | 100 participants (Actual) | Observational | 2013-10-31 | Terminated (stopped due to Ran out of funds) | |||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for atenolol and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bundle-Branch Block; Death, Sudden, Card | 2009 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Death, Sudden, Cardiac; Double-Blind Met | 2007 |
PROTECT (Prospective Reinfarction Outcomes in the Thrombolytic Era Cardizem CD Trial): a randomized, double-blind clinical trial of diltiazem versus atenolol in secondary prophylaxis post non-Q wave myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Calcium Channel Blockers; Death, Sudden, Cardiac; Dilt | 1996 |
Heart rate variability after acute myocardial infarction in patients treated with atenolol and metoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Autonomic Nervous System; Cross-Over Studies; De | 1997 |
Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. Beijing Collaborative Study Group.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Cardiac Outpu | 1997 |
Risk of cardiac events in atypical transient ischaemic attack or minor stroke. The Dutch TIA Study Group.
Topics: Aged; Aspirin; Atenolol; Cerebrovascular Disorders; Death, Sudden, Cardiac; Diagnosis, Differential; | 1992 |
11 other studies available for atenolol and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Severe hypoglycemia-induced sudden death is mediated by both cardiac arrhythmias and seizures.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Anticonvulsants; Arrhythmia | 2018 |
Efficacy of different beta-blockers in the treatment of long QT syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Atenolol; Child; Child, Preschool; Death, Sudden, Ca | 2014 |
Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Comorbidit | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
LIFE: losartan versus atenolol.
Topics: Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Ther | 2003 |
LIFE: losartan versus atenolol.
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diab | 2003 |
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
Unexpected interaction between beta-adrenergic blockade and heart rate variability before and after myocardial infarction. A longitudinal study in dogs at high and low risk for sudden death.
Topics: Animals; Atenolol; Autonomic Nervous System; Death, Sudden, Cardiac; Dogs; Heart; Heart Rate; Longit | 1994 |
Beta-receptor blockade in preventing sudden death.
Topics: Adrenergic beta-Antagonists; Atenolol; Death, Sudden, Cardiac; Humans; Metoprolol; Practolol; Sotalo | 1993 |
Silent myocardial ischemia: some good news.
Topics: Adrenergic beta-Antagonists; Atenolol; Calcium Channel Blockers; Combined Modality Therapy; Coronary | 1997 |
Familial sudden cardiac death associated with a terminal QRS abnormality on surface 12-lead electrocardiogram in the index case.
Topics: Adolescent; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Death, Sudden, Cardiac; Electroc | 1998 |